Glycosaminoglycan and drug compositions containing the same
US6492503B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 22, 2000 |
| Grant date | Dec 10, 2002 |
| Priority date | — |
| Expiry date | May 22, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/143333
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a glycosaminoglycan having a backbone structure comprising a repetitive disaccharide bearing a uronic acid residue and a glucosamine residue, and having sulfate groups, wherein substantially no sulfate group bound to the hydroxyl group at the 6-position of the glucosamine residue in the backbone structure is detected as determined by a chemical disaccharide analysis method in which the glycosaminoglycan is decomposed with nitrous acid, reacted with para-nitrophenylhydrazine and analyzed by high performance liquid chromatography, and the molar % of a uronic acid residue having a sulfate group at the 2-position is not less than 45% relative to total uronic acid residues, which is calculated from a disaccharide composition obtained by an enzymatic disaccharide analysis method in which the glycosaminoglycan is digested with glycosaminoglycan-degrading enzymes and analyzed by high performance liquid chromatography. The glycosaminoglycan can be used as an active ingredient of pharmaceuticals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.